Enterprise Value

-26.43M

Cash

155.8M

Avg Qtr Burn

-27.43M

Short % of Float

3.79%

Insider Ownership

4.71%

Institutional Own.

61.92%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AFM13 + AB-101 Details
Cancer, Hodgkin Lymphoma, peripheral T-cell lymphomas

Phase 2

Initiation

AFM13 Details
Peripheral T cell cancer , Cancer

Phase 2

Initiation

Phase 1/2

Data readout

AFM24 (tumor target EGFR) Monotherapy Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma, Colorectal cancer

Phase 1/2

Update

AFM28 Details
Cancer, Blood cancer, Leukemia, Acute myeloid leukemia

Phase 1

Data readout

RO7297089 (formerly AFM26) Details
Multiple myeloma, Cancer

Failed

Discontinued